Open Access

Immune-enrichment of insulin in bio-fluids on gold-nanoparticle decorated target plate and in situ detection by MALDI MS

Clinical Proteomics201714:5

DOI: 10.1186/s12014-017-9139-z

Received: 10 June 2016

Accepted: 6 January 2017

Published: 19 January 2017

Abstract

Background

Detection of low-abundance biomarkers using mass spectrometry (MS) is often hampered by non-target molecules in biological fluids. In addition, current procedures for sample preparation increase sample consumption and limit analysis throughput. Here, a simple strategy is proposed to construct an antibody-modified target plate for high-sensitivity MS detection of target markers such as insulin, in biological fluids.

Methods

The target plate was first modified with gold nanoparticle, and then functionalized with corresponding antibody through chemical conjugation. Clinical specimens were incubated onto these antibody-functionalized target plates, and then subjected to matrix assisted laser desorption ionization mass spectrometry analysis.

Results

Insulin in samples was enriched specifically on this functional plate. The detection just required low-volume samples (lower than 5 µL) and simplified handling process (within 40 min). This method exhibited high sensitivity (limit of detection in standard samples, 0.8 nM) and good linear correlation of MS intensity with insulin concentration (R2 = 0.994). More importantly, insulin present in real biological fluids such as human serum and cell lysate could be detected directly by using this functional target plate without additional sample preparations.

Conclusions

Our method is easy to manipulate, cost-effective, and with a potential to be applied in the field of clinical biomarker detection.

Keywords

Insulin MALDI MS Antibody-enrichment Chemical conjugation

Background

The level of insulin in the blood indicates explicitly the function of endocrine beta cells, and thus the metabolism situation of carbohydrates and fat. Thus, insulin is recognized as a marker protein for diagnosis of various types of diabetes and related diseases [16]. The detection of insulin in diabetes samples has been used in early-diagnosis, monitoring disease progression, prognosis and pathology research [2]. The progression of technique for insulin analysis will undoubtedly improve the early diagnosis for relative disease and facilitate the follow-up therapy [3, 4].

Currently, insulin analysis is based on a number of methods, including chemiluminescence immunoassays [7], radio immunoassays [8], immune affinity chromatography-LC/MS/MS methods [9], surface plasma resonance immunosensors [10], capillary electrophoretic immunoassay [11], and immune enzymometric assays [12]. However, most of these methods are time- and labor-consuming, of low analysis throughput, and use hazardous reagents such as the radioactive labels.

Matrix assisted laser desorption ionization mass spectrometry (MALDI MS) is a powerful tool for the detection and analysis of biomarkers [13]. Owing to the remarkable features such as high-throughput, high sensitivity, label-free analysis and ease to manipulate, MALDI MS-based analysis has gained considerable interest and is now widely utilized in different fields of biomolecule analysis (including discovery, identification and monitoring), and even as a diagnostic platform [1417]. Nevertheless, directly detecting low-level biomolecules such as insulin is hampered by the complex composition of real biological fluids. The concentrations of target peptide or protein in blood generally range from nM to μM [18], which were much lower than many other non-target molecules and thus very hard to detect or quantify. In addition, the performance of MS is usually hampered by the high content of salts in biological fluids, known as the effect of ionization suppression [19]. Therefore, several immune-MALDI MS methods have been developed to pre-concentrate target analytes and increase analyzing efficiency. These methods generally applied immune-affinity column [20] or antibody-conjugated magnetic beads [21, 22] to capture target biomolecules, followed by MALDI MS analysis. However, these strategies required additional steps of centrifugation, sample transferring, or column-fractions, which increased sample consumption and limited the analysis throughput [13].

One solution is to specifically enrich target molecules on the MS target plate, to avoid additional handling processes such as column purification or sample transfer. A small number of studies have reported the use of this strategy to detect insulin [2325]. In these reported methods, the antibody of target analyte was immobilized on 2-dimension planar substrate by using complicated chemical reagents [23, 24] or non-specific adsorption [25]. However, the surface area of 2-dimension planar substrate was restricted, limiting the number of immobilized antibodies and the approach of target analytes [2325]. Meanwhile, the complex organic chemicals such as dextran [24] may also introduce more non-target signals to MS analysis. Thus, the sensitivities of these strategies were generally in micromole range, hindering a more wide-spread application for the analysis of real biological fluids [23, 25]. Therefore, new design of target plate substrate is still needed to direct analyze real biological fluids using MADLI MS with minimum sample preparation.

Here, to achieve facilitated and sensitive insulin detection, we designed a simple strategy to immobilize insulin antibody directly onto a gold-nanostructured MALDI plate by means of chemical conjugation. The 3-dimension non-planar nano-surface increased surface area, and improved the efficiency of antibody binding, thus enhanced the sensitivity of analysis. Meanwhile, the simple small-molecular chemicals used in this platform avoided introducing interference signals in the MALDI MS. Compared with most previous immune-MALDI MS methods [2022], this platform could simultaneously enrich and detect target insulin in biological fluids without any off-plate purification by affinity-beads/column, requiring a very small quantity of samples and oversimplified handling process.

Methods

Materials

3-Aminopropyltrimethoxysilane (APTMS), 2,5-dihydroxybenzoic acid (DHB), Trifluoroacetic acid (TFA), bovine serum albumin (BSA), human serum albumin (HSA), transferring, immunoglobulin G (IgG), Acetonitrile (ACN), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride were purchased from Sigma (St. Louis, Mo, USA). 11-mercaptoundecanoic acid (MUA) was obtained from Aldrich (Milwaukee, WI, USA). N-Hydroxysuccinimide (NHS) was purchased from Acros (New Jersey, USA). HAuCl4 was purchased from J&K Scientific Ltd. (Beijing, China). NaOH, NaCl, HCl, HNO3, absolute ethanol, methanol, ethanolamine (EOA) were of analytical reagent grade from Beijing Chemical Works (Beijing, China). Antibody of human insulin was purchased from the Cell Signaling Technology, Inc. ITO slides (10 Ω/sq) were purchased from Kaivo Electronic Components Co., Ltd. (Zhuhai, China). All reagents and solvents were used as received. Triply distilled water was used for the preparation of all solutions and rinsing.

Preparation of GNP

The gold nanoparticles (GNP) were prepared according to the previous literature [26]. All glassware used was cleaned in aqua regia solution (HCl:HNO3 = 3:1) and then thoroughly rinsed by distilled H2O. Briefly, 100 mL of 0.01% HAuCl4 was heated to boiling in a round-bottom flask equipped with a condenser. Then 1.3 mL aqueous solution of sodium-citrate (1%) was added under vigorous stirring. In about 25 s, the solution turned blue; in approximately 1 min, the blue color change to red-violet gradually. After that the solution was kept boiling for an additional 10 min, and then cooled at room temperature. The prepared nanoparticle was stored at 4 °C.

Surface modification of ITO slide

Silylation of ITO slide

The ITO glasses were cut into 25 × 37.5 mm slides and cleaned by sequential sonication in acetone for 20 min, in isopropanol for 20 min, in soap water for 15 min, and twice in distilled water for 10 min. The cleaned ITO slides were immersed in 5 M NaOH for 8 h at room temperature and then flushed thoroughly with distilled water and dried under N2 stream. Afterwards they were immediately treated in a freshly prepared APTMS solution (3% in methanol) for 2 h. The resulting APTMS-ITO slides were sonically cleaned in methanol for three times and dried under N2 stream.

Deposition of GNP on APTMS-ITO

The APTMS-ITO slides were immersed in GNP solution for at least 8 h at 4 °C prior to flushing with distilled water and dried under N2 stream.

Derivatization of carboxyl group on GNP-ITO slide

The GNP deposited ITO (GNP-ITO) slides were immersed in a solution of MUA in ethanol (10 mM) for 8 h, rinsed with ethanol, and then dried under N2 stream.

Immobilization of protein on MUA-GNP-ITO

To covalently attach protein on these two kinds of substrate, an aqueous solution of EDC (75 mM) and NHS (15 mM) was first applied to treat the slides for 25 min at room temperature. Then the protein solutions (anti-insulin or BSA in pH 7.4 phosphate buffer) were spotted directly on the proper locations of the slides using pipettor. After all samples were spotted, the slides were laid in a sealed humid bottle at room temperature for at least 2 h to complete coupling reaction. Then an aqueous solution of EOA (1 M, adjusted with 5 M HCl to pH 8.6) was applied to treat the slides for 1.5 h to block the unreacted carboxyl groups. Finally, the anti-insulin or BSA modified ITO slides were flushed thoroughly with water to clean the unbound proteins and dried under N2 stream.

Insulin immune-reaction and MALDI-TOF analysis

Human insulin (0–72 nM) was dissolved in pH 7.4 phosphate buffer (10 mM) or PBS buffer containing albumin (35 mg/mL), transferring (2 mg/mL) and IgG (6 mg/mL) to generate standard insulin solutions. Five microliter of insulin solution was dropped on the anti-insulin modified ITO slide and incubated on a shaking table at room temperature for 30 min. Then the ITO plate was rinsed with Tween 20 solution (0.05% Tween 20 in water) and distilled water sequentially and dried under N2 stream. After that, 1 μL of DHB (15 mg/mL, 50% ACN, 0.1% TFA) was applied as the matrix for MALDI-TOF mass analysis. The solvent was dried naturally under room temperature and then the target plate was subjected to MALDI MS analysis.

Mass spectrometry was acquired on SHIMADZU AXIMA Resonance MALDI-IT-TOF on reflective/positive ion mode. Laser power of 105 mV was selected as standard desorption energy in MS analysis.

Results and discussion

Strategy to anchor insulin antibody on MALDI MS target plate

An indium tin oxide coated glass slide (ITO slide) was selected as MALDI MS target plate due to its ease of chemical modification and excellent conductivity [26], the latter is important for the efficient MALDI MS analysis [25]. An easy approach to construct nano-surface was designed, and used to immobilize the insulin antibody on the ITO slide by chemical conjugation.

The approach (Fig. 1) utilized gold-nanoparticle (GNP) to modify ITO surface. Three key steps were needed: derivatization of amino group on ITO slide with silanization reagent APTMS [27]; deposition of GNP on the amino-terminated ITO slides [26]; derivatization of carboxyl group on the GNP-ITO and chemical coupling of antibody. The GNP with negative charged surface could be adsorbed stably on the amino-terminated ITO surface through electrostatic interactions [26]. Compared with the 2-dimension planar surface of original ITO, the 3-dimension nano-structure would greatly increase the surface area of target plate. Correspondingly, the antibodies immobilized on plate surface increased, which was beneficial for capturing more insulin and increasing MS sensitivity [6]. A key factor to affect detection was the laser energy of MALDI MS, because weak laser power may not desorb the insulin immobilized by antibody. As shown in Fig. 2, when the laser energy was lower than 65 mV, the signal was hardly detected. The MS signal intensity increased gradually as laser energy rose from 65 to 105 mV, and kept stable after laser energy exceeded 105 mV (Fig. 2). Because excessive laser energy may introduce additional noisy signal, we chose 105 mV as standard laser energy in our experiments to achieve the best signal intensity.
Fig. 1

Schematic overview for the preparation of GNP-modified target plate and antibody-assisted enrichment and MS-detection of insulin

Fig. 2

MALDI MS intensity of standard insulin sample (8 nM) obtained at different laser energy power (45, 65, 85, 105, and 120 mV). Data represent MEAN ± SEM, n ≥ 3

To prove the validity of this approach, either insulin antibody or a control protein BSA were covalently anchored on the GNP-ITO slides. Subsequently, standard solutions of insulin were incubated on these two protein-modified plates, and then washed to remove any unbound or weakly bound species. As shown in Fig. 3a, on the BSA modified GNP-ITO (without antibody), no insulin signal could be detected (Fig. 3a). Meanwhile, by using the antibody-modified GNP-ITO as target plate, clear signal of insulin was identified (Fig. 3b), indicating that the insulin in samples was captured on the antibody-functionalized plate and then detected by MALDI MS. Notably, there is no other noisy signals visible in the mass range, indicating that the designed target plate did not introduce interfering signals in this range.
Fig. 3

MALDI MS spectra of standard insulin samples (8 nM). a MS Spectrum achieved on BSA modified GNP-ITO without anti-insulin antibody. b MS Spectrum achieved on anti-insulin antibody-modified GNP-ITO. 5 Replicates for each data were tested at the same conditions

To exclude the possibility of capturing non-target molecules on the antibody-modified GNP-ITO, a mixture solution of insulin (34 nM) and non-target peptide (331 nM) was analyzed by using different target plates. As shown in Fig. 4, no recognizable peak can be observed on the BSA modified GNP-ITO (Fig. 4a). In addition, the conventional MALDI MS plate demonstrated abundance of both two peptides (Fig. 4b). As no separation method employed, the insulin signal was much lower than C-peptide (Fig. 4b). In contrast, on the antibody-modified target plate, the signal of C-peptide disappeared and only the clear peak of insulin was observed in spectrum (Fig. 4c). These evidences revealed that the antibody have been immobilized substantially on the target plate and specifically capture the target insulin in samples as we expected.
Fig. 4

MALDI MS spectra of standard insulin (34 nM)/C-peptide (331 nM) mixture solution. a MS Spectrum achieved on BSA modified GNP-ITO without anti-insulin antibody. b MS Spectrum achieved on conventional target plate. c MS Spectrum achieved on anti-insulin antibody-modifed GNP-ITO. 5 Replicates for each data were tested at the same conditions

Sensitivity of the MALDI MS based on the anti-insulin modified GNP-ITO

Standard insulin samples at different concentrations were tested on the antibody-modified GNP-ITO. Five microliters of insulin solution were incubated on a circular area (diameter 4 mm) of the target plate for 30 min followed by washing with Tween 20 solution (0.05%) and water. After drying, DHB (15 mg/mL in 50% ACN, 0.1% TFA) was spotted on the circular area as MS matrix and the target plate was subjected to MALDI MS analysis. As illustrated in Fig. 5, strong signals of insulin at m/z 5809 and 5791 were clearly detected. The insulin peaks could be resolved from the background (≥3 times of baseline intensity) even when the insulin level was as low as 0.8 nM. The limit of detection (LOD) at 0.8 nM obtained in standard solution is much lower than the previous reported similar works, in which the tested peptide levels were usually at the range of micromole [25] or several hundred nano-moles [24]. A good linear correlation (R2 = 0.994) of MS intensity with insulin level was obtained in the range of 0.8–48 nM (Fig. 6). We also tried to test the performance of our method in complex bio-fluids. Due to the difficulty to obtain insulin-free serum, we tried to mimic the serum by generating a buffer solution containing serum-abundant proteins such as albumin (35 mg/mL), transferring (2 mg/mL) and IgG (6 mg/mL), which were added at the concentrations similar to real serum. As shown in Fig. 6, although the MS intensity of insulin based on artificial matrix was lower than PBS buffer, a linear relation with R2 = 0.985 still could be observed in the range lower than 32 nM (Fig. 6). These results demonstrated the ability of our method to perform real bio-fluid analysis, and that the interference from sample matrix was limited.
Fig. 5

MALDI MS spectra of standard insulin samples in different concentrations (0.8, 1.6, 4, 8, 16, 32, 48 nM) achieved on anti-insulin antibody-modified GNP-ITO. 3 Replicates for each data were tested at the same conditions

Fig. 6

Correlation of MS intensity with the concentrations of insulin (0.8, 1.6, 4, 8, 16, 32, 48, 60, and 72 nM) spiked in PBS buffer (blue circle) or artificial serum-mimic (red square) containing albumin (35 mg/mL), transferring (2 mg/mL) and IgG (6 mg/mL). Data represent MEAN ± SEM. n ≥ 3

A serial of parallel serum samples collected from 6 patients accepting insulin therapy were also tested to investigate the reproducibility. Good repeatability was obtained in within and between day tests, as shown in Table 1. In short, sensitive detection of insulin was easily achieved on this developed target plate, just requiring very low-volume sample and oversimplified handling process.
Table 1

Repeatability of MALDI MS results obtained on antibody-modified GNP-ITO in 6 patient serum samples (accepting insulin therapy)

 

Mear (MS intensity)

CV% for within day

CV% for between day

Patient 1

2.50

15.8

17.0

Patient 2

4.52

13.8

14.8

Patient 3

4.11

14.1

15.3

Patient 4

3.28

15.0

15.3

Patient 5

4.47

11.1

14.6

Patient 6

3.67

15.1

16.0

Ten replicate measurements per sample per day were performed for 3 days to generate 30 values per sample

Analysis of biological fluids

It is difficult to directly detect low-level targets in complex samples using MALDI MS. The complicated composition and high level non-target molecules in biological fluids generally generated high background signals and interfered with the detection of target molecules. In addition, salts present in samples will greatly reduce the performance of MS analysis. Figure 7a indicated the MS spectrum by applying raw human serum (from the patients accepting insulin therapy) on the conventional MALDI plate, and no identified signals can be observed at m/z 5809 and 5791. Subsequently, the human sera were incubated and washed on the antibody-modified GNP-ITO and then subjected to MALDI MS analysis. As shown in Fig. 7b, the signals of insulin at m/z 5809 and 5791 were discerned clearly from the background, representing a significant improvement compared with conventional MALDI MS methods. According to the MS intensity, the concentrations of insulin in these serum samples were calculated as shown in Table 2. Compared to the insulin level obtained by clinically standard chemiluminescence immunoassays (CIA), the immune-MS results did not show significant difference, with a p value >0.05 (p = 0.3383, Table 2; Fig. 8). Meanwhile, strong correlation of the results tested by CIA with immune-MALDI MS was also observed (correlation coefficient >90%).
Fig. 7

MALDI MS spectra of human serum samples. a MS Spectrum achieved on conventional target plate. b MS Spectrum achieved on anti-insulin antibody decorated GNP-ITO. 3 Replicates for each data were tested at the same conditions

Table 2

Insulin levels in 6 human serums tested by chemiluminescence immunoassays (CIA) and the developed immune-MS method

 

Serums of patients (accepting insulin therapy)

#1

#2

#3

#4

#5

#6

CIA (nM)a

1.0

3.6

3.2

2.1

3.5

2.3

MS (nM)b

1.3

3.8

3.3

2.2

3.8

2.4

5 Duplicates of each sample were tested by MALDI MS based on antibody-modified target plate and CIA

a CIA chemiluminescence ImmunoAssays

b MS MALDI MS based on antibody-modified target plate

Fig. 8

Comparison of serum insulin levels tested by chemiluminescence immunoassays (CIA) and the MALDI MS based on antibody-modified GNP-ITO (MS). Differences with p values <0.05 were considered statistically significant. Data represent MEAN ± SEM

In addition, we measured the lysate fluid of rat pancreas cell using this developed target plate. The amino acid sequences of rat insulin ([M + H]+=5805 Da) and human insulin ([M + H]+=5809 Da) although differ by several amino acids, the rat insulin could still be recognized by the anti-insulin we applied. The MS spectrum (Fig. 9) revealed that the rat insulin in lysate fluid also could be directly detected, with a concentration calculated of around 14 nM. These results further exhibited the feasibility of this method for bio-fluids analysis.
Fig. 9

MALDI MS spectrum of cell lysate in rat pancreas achieved on anti-insulin antibody-modified GNP-ITO. 3 Replicates for each data were tested at the same conditions

Conclusion

Here, we proposed a strategy to construct antibody-functionalized MALDI target plate for fast and high-throughput MS analysis of insulin. The nanostructure on the surface of target plate improved the efficiency of antibody coupling and insulin detection. Biological fluids, such as serum or cell lysate, could be sensitively analyzed using this functional target plate without any pre-purification, which is impossible for the conventional MALDI MS methods. Furthermore, our method is also useful for the immobilization of other antibodies and analysis of other types of biomolecules, thus offering a widely-used toolbox for the fields of bio-sample exploration.

Abbreviations

APTMS: 

3-aminopropyltrimethoxysilane

DHB: 

2,5-dihydroxybenzoic acid

TFA: 

trifluoroacetic acid

BSA: 

albumin bovine serum

ACN: 

acetonitrile

EDC: 

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

MUA: 

11-mercaptoundecanoic acid

NHS: 

N-hydroxysuccinimide

EOA: 

ethanolamine

ITO: 

indium tin oxide

GNP: 

gold nanoparticles

MALDI MS: 

matrix assisted laser desorption ionization mass spectrometry

Declarations

Authors’ contributions

KL carried out the construction of functionalized target plates, MALDI MS experiments, data analyses and participated in drafting the manuscript. HW contributed to the preparation of standard, clinical and animal samples, and clinical information. YL conceived the study, contributed to its design and coordination, participated in drafting the manuscript and critical review. All authors read and approved the final manuscript.

Acknowledgements

Help from Torsten Juelich in Peking University for assistance with discussion and editing is greatly acknowledged.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The authors declare that all the data and materials are available.

Ethics approval and consent to participate/publication

A total of 6 serum samples were collected at the time of diagnosis from Peking University First Hospital after approval by the Ethic Review Board of the hospital. All patients gave written informed consent for study participation and consent for publications to this hospital (IRB PA20140929).

Funding

This work was supported from the Major State Basic Research Development Program of China (973 Program), Grant 2013CB910100 (Y. L.), and the Key Research Program of the Chinese Academy of Sciences, Grant KJZD-EW-TZ-L05 (Y. L.).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Interdisciplinary Research, Institute of Biophysics, Chinese Academy of Sciences
(2)
GuangDong Bio-healtech Advanced Co., Ltd

References

  1. Hu Y, Fine DH, Tasciotti E, Bouamrani A, Ferrari M. Nanodevices in diagnostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(1):11–32.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Darmanis S, Nong RY, Hammond M, Gu JJ, Alderborn A, Vanelid J, Siegbahn A, Gustafsdottir S, Ericsson O, Landegren U, Kamali-Moghaddam M. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics. 2009;9:327–35.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Arruda DL, Wilson WC, Nguyen C, Yao QW, Caiazzo RJ, Talpasanu I, Dow DE, Liu BCS. Microelectrical sensors as emerging platforms for protein biomarker detection in point-of-care diagnostics. Expert Rev Mol Diagn. 2009;9:749–55.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Swierczewska M, Liu G, Lee S, Chen XY. High-sensitivity nanosensors for biomarker detection. Chem Soc Rev. 2012;41:2641–55.View ArticlePubMedGoogle Scholar
  5. Pu Y, Zhu Z, Han D, Liu HX, Liu J, Liao J, Zhang KJ, Tan WH. Insulin-binding aptamer-conjugated graphene oxide for insulin detection. Analyst. 2011;136:4138–40.View ArticlePubMedGoogle Scholar
  6. Zhang XY, Zhu SC, Deng CH, Zhang XM. An aptamer based on-plate microarray for high-throughput insulin detection by MALDI-TOF MS. Chem Commun. 2012;48:2689–91.View ArticleGoogle Scholar
  7. Zaitsu K, Kimura Y, Ohba Y, Hamase K, Motomura Y, Itose M, Ishiyama M. Heme-undecapeptide labeling on insulin for the immunoassay of insulin with chemiluminescence detection. Anal Sci. 1999;15(9):871–8.View ArticleGoogle Scholar
  8. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme-immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;39(4):578–82.PubMedGoogle Scholar
  9. Ho ENM, Wan TSM, Wong ASY, Lam KKH, Stewart BD. Doping control analysis of insulin and its analogues in equine urine by liquid chromatography–tandem mass spectrometry. J Chromatogr A. 2011;1218:1139–46.View ArticlePubMedGoogle Scholar
  10. Gobi KV, Iwasaka H, Miura N. Self-assembled PEG monolayer based SPR immunosensor for label-free detection of insulin. Biosens Bioelectron. 2007;22:1382–9.View ArticlePubMedGoogle Scholar
  11. Jia M, He Z, Jin W. Capillary electrophoretic enzyme immunoassay with electrochemical detection for cortisol. J Chromatogr A. 2002;966:187–94.View ArticlePubMedGoogle Scholar
  12. Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer JP, Winter WE, Skyler JS, Krischer JP. Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. Clin Chim Acta. 2011;412:2128–31.View ArticlePubMedGoogle Scholar
  13. Madian AG, Rochelle NS, Regnier FE. Mass-Linked Immuno-Selective Assays in Targeted Proteomics. Anal Chem. 2013;85(2):737–48.View ArticlePubMedGoogle Scholar
  14. Calligaris D, Villard C, Lafitte D. Advances in top-down proteomics for disease biomarker discovery. J. Proteomics. 2011;74:920–34.View ArticlePubMedGoogle Scholar
  15. Chao T-C, Hansmeier N, Halden RU. Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery. J Proteomics. 2010;73:1641–6.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683–95.View ArticlePubMedGoogle Scholar
  17. Zhang X, Zhu S, Deng C, Zhang X. Highly sensitive thrombin detection by matrix assisted laser desorption ionization-time of flight mass spectrometry with aptamer functionalized core–shell Fe3O4@C@Au magnetic microspheres. Talanta. 2012;88:295–302.View ArticlePubMedGoogle Scholar
  18. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at sub femtomolar concentrations. Nat Biotechnol. 2010;28:595–9.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Knochenmuss R. A bipolar rate equation model of MALDI primary and secondary ionization processes, with application to positive/negative analyte ion ratios and suppression effects. Int J Mass Spectrom. 2009;285(3):105–13.View ArticleGoogle Scholar
  20. Klaus M, Per MU. Targeted quantification of C-reactive protein and cystain C and its variants by immnuo-MALDI-MS. Anal Chem. 2014;86:5807–14.View ArticleGoogle Scholar
  21. Jennifer DR, Daniel TH, Randal M, Brinda S, Christoph HB. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom. 2010;21:1680–6.View ArticleGoogle Scholar
  22. Alexander GC, Jessica GG, Robert P, Daniel TH, Christoph HB. Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension. Clin Proteomics. 2013;10:20.View ArticleGoogle Scholar
  23. Brockman AH, Orlando R. Probe-immobilized affinity chromatography/mass spectrometry. Anal Chem. 1995;67:4581–5.View ArticlePubMedGoogle Scholar
  24. Brockman AH, Orlando R. New immobilization chemistry for probe affinity mass spectrometry. Rapid Commun Mass Spectrom. 1996;10:1688–92.View ArticlePubMedGoogle Scholar
  25. Yang M, Chao T-C, Nelson R, Ros A. Direct detection of peptides and proteins on a microfluidic platform with MALDI mass spectrometry. Anal Bioanal Chem. 2012;404:1681–9.View ArticlePubMedGoogle Scholar
  26. Wang L, Wang EK. A novel hydrogen peroxide sensor based on horseradishperoxidase immobilized on colloidal Au modified ITO electrode. Electrochem Commun. 2004;6:225–9.View ArticleGoogle Scholar
  27. Liang K, Chen Y. Elegant chemistry to directly anchor intact saccharides on solid surfaces used for the fabrication of bioactivity-conserved saccharide microarrays. Bioconjugate Chem. 2012;23:1300–8.View ArticleGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement